Lineage Cell Therapeutics, Inc. (LCTX) Total Return Calculator with Dividends Reinvested

Lineage Cell Therapeutics, Inc.

Popular:

The total return for Lineage Cell Therapeutics, Inc. (LCTX) stock is +32.23% over the past 12 months. So far it's down 26.22% this year. The 5-year total return is -55.19%, meaning $10,000 invested in LCTX stock 5 years ago would be worth $4,481 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in LCTX 1 year ago, it would be worth $12,612 today — you'd have gained $2,612.

With Dividends Reinvested$12,612+26.12%

Price Only (No DRIP)$12,612+26.12%

Period2025-06-23 → 2026-06-18

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in LCTX

1Y$13,223+$3,223 (+32.2%)32.2% CAGR

3Y$8,176-$1,824 (-18.2%)-6.5% CAGR

5Y$4,481-$5,519 (-55.2%)-14.8% CAGR

10Y$4,899-$5,101 (-51.0%)-6.9% CAGR

15Y$2,834-$7,166 (-71.7%)-8.1% CAGR

20Y$50,416+$40,416 (+404.2%)8.4% CAGR

30Y$1,876-$8,124 (-81.2%)-5.4% CAGR

Lineage Cell Therapeutics, Inc. did not pay dividends during this period. Total return = price return.

Loading LCTX total return...

As of 2026-06-22

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-26.22%	—	-26.22%	—	$7,378
1Y	+32.23%	32.23%	+32.23%	—	$13,223
3Y	-18.24%	-6.49%	-18.24%	—	$8,176
5Y	-55.19%	-14.83%	-55.19%	—	$4,481
10Y	-51.01%	-6.89%	-51.01%	—	$4,899
15Y	-71.66%	-8.06%	-71.66%	—	$2,834
20Y	+404.16%	8.42%	+404.16%	—	$50,416
30Y	-81.24%	-5.42%	-82.40%	+1.16 pp	$1,876

Risk & Highlights

Best Year+646.66%1996

Worst Year-79.47%2005

Max Drawdown-39.29%2026-02-26 → 2026-06-05

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	+17.07%	+17.07%	—	+0.41%	+16.7pp
2025	+224.27%	+224.27%	—	+16.64%	+207.6pp
2024	-53.90%	-53.90%	—	+24.00%	-77.9pp
2023	-11.38%	-11.38%	—	+24.81%	-36.2pp
2022	-52.82%	-52.82%	—	-19.95%	-32.9pp

LCTX outperformed the S&P 500 by 7.24pp over the past year (+32.23% vs +24.99%).

Loading summary...

LCTX Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
LCTXLineage Cell Therapeutics, Inc.	$302M	-2.4%	-26.2%	+32.2%	—	-18.2%	-55.2%	-51.0%
FATEFate Therapeutics, Inc.	$244M	+20.8%	+111.1%	+72.7%	—	-64.4%	-97.4%	+4.5%
NTLAIntellia Therapeutics, Inc.	$1.8B	+23.5%	+70.1%	+63.2%	—	-64.1%	-79.4%	-43.2%
BEAMBeam Therapeutics Inc.	$3.5B	+27.3%	+25.8%	+100.9%	—	+2.4%	-59.8%	+82.1%
EDITEditas Medicine, Inc.	$263M	+6.3%	+31.2%	+14.5%	—	-67.8%	-92.5%	-90.9%
CRSPCRISPR Therapeutics AG	$5.2B	+11.4%	+0.6%	+21.7%	—	-4.9%	-57.7%	+283.9%
OCGNOcugen, Inc.	$420M	-7.5%	-10.1%	+13.8%	—	+124.2%	-81.1%	-98.9%
REPLReplimune Group, Inc.	$841M	+103.4%	+14.5%	+7.4%	—	-56.9%	-71.2%	-32.8%
CELCCelcuity Inc.	$4.3B	-33.6%	-12.7%	+643.1%	—	+680.1%	+236.9%	+514.1%
IOVAIovance Biotherapeutics, Inc.	$1.4B	+15.3%	+55.2%	+91.7%	—	-52.8%	-84.2%	-51.2%
RGNXREGENXBIO Inc.	$403M	+38.1%	-42.5%	-9.0%	—	-61.5%	-79.3%	-18.9%

Compare:LCTX vs FATE LCTX vs NTLA LCTX vs BEAM LCTX vs FATE vs NTLA

About LCTX Dividend Returns

Lineage Cell Therapeutics, Inc. (LCTX) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of LCTX over the past year?

Lineage Cell Therapeutics, Inc. (LCTX) delivered a return of 32.23% over the past year. Since LCTX does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in LCTX be worth today?

A $10,000 investment in Lineage Cell Therapeutics, Inc. one year ago would be worth $13,223 today, representing a gain of $3,223.

Q3Does LCTX pay dividends?

Lineage Cell Therapeutics, Inc. (LCTX) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For LCTX, the total return equals the price-only return.

Q4Did LCTX beat the S&P 500?

Yes, Lineage Cell Therapeutics, Inc. (LCTX) outperformed the S&P 500 by 7.24 percentage points over the past year. LCTX delivered a total return of 32.23%, compared to the S&P 500's 24.99%. This 7.24pp alpha means investors in LCTX earned more than a passive S&P 500 index fund.

Q5What is LCTX's worst drawdown?

Lineage Cell Therapeutics, Inc. (LCTX) experienced a maximum drawdown of -39.29% over the past year, declining from its peak on 2026-02-26 to its trough on 2026-06-05. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is LCTX's long-term total return over 10, 20, or 30 years?

Here are Lineage Cell Therapeutics, Inc. (LCTX)'s long-term returns with dividends reinvested. Over 10 years, the total return is -51.0% (-6.9% CAGR) — $10,000 would have grown to $4,899. Over 20 years: 404.2% total return (8.4% CAGR) — $10,000 → $50,416. Over 30 years: -81.2% total return (-5.4% CAGR) — $10,000 → $1,876. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was LCTX's best and worst year?

Lineage Cell Therapeutics, Inc.'s best calendar year was 1996 with a total return of 646.7%. Its worst year was 2005 with a total return of -79.5%. This range shows the volatility investors should expect — the difference between the best and worst year is 726.1 percentage points.

How much would $100/month in LCTX be worth today?

Dollar cost averaging calculator · DCA vs lump sum · see how regular investing compounds

Run the Numbers →